本帖最后由 老马 于 2012-1-13 21:20 编辑
9 ~7 X8 e. y- _
4 z- n: D0 O0 n. [# N. u+ _爱必妥和阿瓦斯丁的比较
_ Q. ~7 j9 P) Y* Y
- Y" B d) [/ J. e. }) Bhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/6 {: A8 R9 o ]
' g# u( N4 w4 j5 H. F
: w& C8 T( l9 Q K7 Ghttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
( ^2 w& R" k5 i& h! h; {$ m7 l7 t==================================================
! i, F( |5 S3 |Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)2 e6 a" y4 s: q1 C4 b
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point./ @6 p) a! o6 f3 s9 ?! O
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
% i$ B% h% Z( p% R) Y6 `
|